Vienna, 21.09.2023. Sofia Opitz has joined AOP Orphan Pharmaceuticals GmbH (“AOP Health”) as Nordic Managing Director. She has more than 25-years of experience in the Nordic pharmaceutical markets and prior to joining AOP Health she worked as Country Manager for Sweden, Norway, and Denmark at BIOCODEX.
Sofia Opitz is Managing Director of AOP Health Nordics
September 21st 2023
Sofia Opitz is New Managing Director of AOP Orphan Pharmaceuticals Sweden AB – a Member of the AOP Health Group.
Sofia Opitz
My goal is to expand our business in the region together with the AOP Health Nordic Team and support more patients with rare and critical diseases.
Achieving ambitious goals
Opitz started her career as a Sales Representative at Pharmacia Sverige AB Consumer Healthcare, where she soon became Product Manager of multiple brands. She also held several senior positions within Pfizer, Nestlé, Novartis, and Fresenius-Kabi. In these positions she found a passion to lead country and commercial operations.
Throughout her career, Opitz has gained experience in strategy planning at a global level and has acquired leadership skills that help her in achieving ambitious goals. Sofia Opitz about her new position: “I am truly impressed by the dynamic culture within AOP Health and also the strong pipeline. I am looking forward to joining a growing company and helping patients.”
Michael Kindell
Sofia is a positive and energetic person, who convinces with her leadership skills. Her willingness to confront a problem head on and her strategic approach make her a perfect fit for AOP Health.
About AOP Health
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. The claim “Needs. Science. Trust.” sums up the foundation of the Group’s success: establishing trust through a continually high level of investment in research and development and a highly consistent and pragmatic orientation towards the needs of all stakeholders – especially the patients and their families as well as the healthcare professionals treating them.